Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Users of Remote Conferencing and Compression of Sound Dynamics : Auditory Effects

NCT06264245 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-06-01
Last updated
2025-03-03

Condition(s) studied

Auditory Perception

Investigational drug(s) / intervention(s)

Audiological profileHearing self-assessmentsObjective and subjective audiological testsSelf-assessment of exposure sound quality

Audiological profile: Video otoscopy Tympanometry High-frequency tonal audiometry

Hearing self-assessments: Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire

Objective and subjective audiological tests: Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test

Self-assessment of exposure sound quality: A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.

Study summary

The COMPRESSED project is a descriptive, bi-centric and non-invasive study carried out by the CERIAH - IDA - Institut Pasteur and the Haute École Léonard de Vinci in Brussels on volunteer participants identified in two groups :

* be subject to high exposure to compressed sound, as defined by professional participation in events on broadcast platforms using sound signal processing systems, over the last 3 years,
* be subject to moderate or limited exposure to compressed and manipulated sound, equivalent to that of a student following certain distance learning courses. on a videoconferencing platform, alternating with other face-to-face courses, with the ability to listen during breaks, which have been taught for a maximum of 2 years.

The main objective of the COMPRESSED study is to evaluate the auditory effects of exposure to manipulated sounds (compression, filtering, equalisation, accentuation, etc.) from sound distribution platforms on the auditory system of participants who are regularly exposed to these sounds as a result of their professional activity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: For all participants: * Age 18 or over, * Work with platforms using sound signal processing systems, * Fluent in English, * Fluent in French, * Declare that they have no hearing loss. For participants in the high exposure group: \- Have had a professional activity over the last three years using broadcasting platforms with sound signal processing systems, For participants in the moderate or limited exposure group: \- Have worked between one semester and two years with platforms using sound signal processing systems. Exclusion Criteria: * Conductive or mixed hearing loss, i.e. where the hearing loss affects both the outer and/or middle ear and the inner ear. * Have an asymmetric hearing loss, i.e. a difference in average hearing loss between the left and right ear of more than 20 dB, * Have a history of otitis and/or an ENT disease that permanently affects hearing (vestibular schwannoma, Ménière's disease, sudden or fluctuating deafness, congenital hypoacusis), * Not fluent in English * Be under guardianship, * Deprived of liberty by judicial or administrative decision, or subject to legal protection.

Primary outcome measure(s)

  • Hearing assessments of participants exposed to manipulated sounds after and before exposure — 2 weeks
    Measurement of the difference between the hearing assessments of participants exposed to manipulated sounds after and before exposure

Trial sites (2)

FacilityCityRegionStatus
Haute Ecole Léonard De Vinci Brussels Belgium Not Yet Recruiting
CEntre de Recherche et d'Innovation en Audiologie Humaine Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06264245 on ClinicalTrials.gov ↗ ← All trials in France